A therapeutic vaccine candidate for lung cancer based on an exclusive cell line of Plasmacytoid Dendritic Cells (PDC*line)

Project Information

PDClungSME1

Grant agreement ID: 735097

DOI 10.3030/735097

Project closed

EC signature date 10 July 2016

Start date 1 August 2016

End date 28 February 2017

Funded under

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Total cost € 71 429,00

EU contribution € 50 000,00

Coordinated by

PDC LINE PHARMA
France